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Abstract
Endothelium is the inner most cell layer of blood vessels. Endothelial cells 
make special barrier that separate blood from extravascular tissues. Intact 
endothelium regulates vascular tone and permeability and maintains non-inflam-
matory, anti-thrombotic surface. Through its ability to express pro-coagulants, 
anticoagulants, vasoconstrictors, vasodilators, cell adhesion molecules, and 
cytokines, the endothelium has emerged as one of the pivotal regulators of 
vascular homeostasis. Under physiological conditions, endothelial cell sustains a 
vasodilatory, anticoagulant, and fibrinolytic state in which coagulation, platelet 
adhesion, as well as leukocyte activation and inflammation are suppressed. In 
contrast, during endothelial disturbances, a prothrombotic and pro-inflammatory 
state of vasoconstriction gets support from the endothelial surface. Release of 
platelet-activating factor (PAF) and endothelin-1 promotes vasoconstriction, 
whereas production of von Willebrand factor (vWF), tissue factor (TF), and 
plasminogen activator inhibitor (PAI)-1 shifts the haemostatic balance towards a 
procoagulant state. Several factors like infection, hyperglycaemia, hyperlipidae-
mia, malignancy, oxidative stress, and aging can interfere in endothelial function. 
It is believed that most of the cardiovascular diseases originate from endothelial 
dysfunction. Endothelial dysfunction has been shown to be involved in athero-
sclerosis, thrombosis, hypertension, diabetes, and other cardiovascular diseases. 
In this review we will specifically highlight the role of endothelial dysfunction in 
development of cardiovascular diseases.
Keywords: endothelial dysfunction, atherosclerosis, hypertension, heart failure, 
stroke
1. Introduction
Vascular endothelium is considered as a largest endocrinal organ in the body, 
which has been shown to have a role in homeostasis in the body by exerting vari-
ous functions [1]. It is made up of simple squamous epithelial cells that line blood 
vessels, lymphatic vessels, and the heart. The vascular endothelium has a total weight 
of about 1.5 kg. The endothelium has been recognized as a smart barrier and a key 
regulator of blood flow in micro- and macro-vascular circulation [2]. Endothelial 
function is very important, as it interacts with nearly every system in the body 
and selectively supplies nutrients and growth factors to every organ. On the other 
hand, endothelium also receives active metabolites and delivers them back to the 
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circulation. Previously, it was believed that, endothelium is an inactive barrier 
between blood and extravascular tissues. However, recent research has shown that 
the vascular endothelium is an active paracrine, endocrine, and autocrine organ that 
is indispensable for the regulation of vascular tone and the maintenance of vascular 
homeostasis.
2. Physiological function of endothelium
When immediate surrounding tissues are at basal conditions, the endothelium 
functions to maintain the vessel homeostasis, which favors vessel dilatation over 
vasoconstriction [3]. The endothelium being a dynamic reactive tissue, responds to 
various intrinsic physical stimuli, that is, shear stress, temperature, and transmural 
pressure and external stimuli, that is, temperature, mental stress, neurohumoral 
responses, immune response, and medications [2, 4].
Under normal conditions, endothelial cell maintains basal perfusion, which is 
determined by cardiac output, systemic, and local vascular resistance. Endothelial 
metabolism, which is a key regulator of perfusion, is impaired during several 
disease states like infection, injury, aging, and inflammation [5]. Local blood flow 
is the result of vascular relaxation and contraction that is balanced by endothelium-
derived vaso-dilatative and vaso-constrictive factors. Among these factors, one 
signal molecule stands out as hub and target of many pathways and mechanisms 
that is nitric oxide (NO) [6]. It is important to understand the biochemical founda-
tions of NO for endothelial function. NO, a potent vasodilator, is released form 
the endothelium due to shear stress. This NO is released by endothelial nitric oxide 
synthase (eNOS) by utilizing L-arginine as a substrate, which leads to the produc-
tion of intracellular cyclic GMP [7]. However, in an event when the NO-dependent 
vasodilator mechanism is compromised, then the cytochrome-derived factors, 
natriuretic peptide [8], and prostacyclin [9]-dependent vasodilator mechanism 
came in action.
During disease state, there is impaired endothelial function, and this results in 
the balance shift towards prevailing constrictive factors and/or down-regulation 
of vaso-dilatative factors. An important counterweight in the vascular balance is 
cyclooxygenase (COX). This mostly induces COX-1 which is endogenous and may 
involve COX-2 if it is induced. The COXs have a key role in generating vasoconstric-
tive factors.
The COX enzymes transform arachidonic acid into endoperoxides and further 
into thromboxane A2 (TXA2) [10], prostaglandins, and prostacyclin [11]. Local 
presence of thrombin evokes inducible NO release. Platelet release of serotonin and 
ADP in turn increases NO synthesis and release in healthy endothelium to induce 
dilatation [12]. When vasodilatory function of endothelium is impaired, then the 
thrombus formation is mechanically promoted by vasoconstriction via TXA2 and by 
the direct effect of serotonin on smooth muscle cells [13].
3. Endothelial dysfunction
Traditionally, endothelial dysfunction has been associated to pathological 
conditions that have altered anticoagulant function, impaired anti-inflammatory 
properties of the endothelium, impaired modulation of vascular growth, and 
dysregulation of vascular remodeling. For instance, a plethora of studies have con-
firmed the impairment of endothelium-dependent vasorelaxation caused by a loss 
of NO bioactivity/availability in the vessel wall [4]. The loss of NO bioavailability 
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is the salient feature of a dysfunctional endothelium, which in turn is the sentinel 
of systemic or focal vascular disease. A number of previous studies have showed 
that most of the cardiovascular diseases were initiated from endothelial dysfunc-
tion. The decline in NO bioavailability may be caused by decreased expression of 
the endothelial cell eNOS [14], a lack of substrate or cofactors for eNOS [15], the 
presence of inhibitor of NOS [16], and alterations of cellular signaling, and finally, 
accelerated NO degradation by ROS [17]. Another aspect of endothelial dysfunction 
is impaired endothelial barrier function. Depending on the mode of pathophysi-
ological change, this loss in barrier function may be localized or systemic. Localized 
loss of the selective barrier function (manifested as edema), coupled with the 
emigration of leukocytes, has been recognized as cardinal signs of inflammation 
[18]. From an immunological context, the body’s primary reaction to tissue injury 
or infection is the leukocyte interacting with endothelium. However, from the 
perspective of hemostasis and thrombosis, endothelial dysfunction is character-
ized by activation of pro-inflammatory and pro-coagulant molecules, as well as the 
suppression of anti-inflammatory and anti-coagulant molecules. The intact and 
normal functioning endothelial lining provides a stable reservoir for blood as its 
luminal surface does not activate the coagulation cascade or promote leukocyte-
platelet adhesion, and it also exhibits anticoagulant and fibrinolytic properties [19]. 
Systemic endothelial dysfunction may lead to widespread inflammation, vascular 
leakage, thrombocytopenia, and disseminated intravascular coagulation (DIC). 
On the other hand, localized endothelial dysfunction and leukocyte adhesion may 
lead to venous thrombosis. Other than altered endothelial barrier function, local-
ized endothelial dysfunction also leads to tissue factor induction and increased 
von Willebrand factor (vWF) release that shifts the homeostatic balance towards 
the pro-coagulant-pro-inflammatory phenotype [20]. Intact endothelium release 
pro-fibrinolytic molecules like tissue plasminogen activator (TPA) [21]. Endothelial 
dysfunction suppressed TPA release, thereby impairing fibrinolytic function 
of endothelium [22]. In contrast to venous endothelial cells and microvascular 
endothelial cells, arterial endothelial cells are surrounded by a vascular smooth 
muscle layer and adventitial layer. Arterial endothelial cells physiologically experi-
ence high sheer stress and synthesize ample amount of NO that facilitate vascular 
relaxation. In the context of atherogenesis, endothelial cell dysfunction is mainly 
characterized by a loss of anatomical integrity of the intima, as described by the 
seminal “Response-to-Injury Hypothesis”. Endothelial cell injury and subsequent 
sub-endothelial matrix exposure lead to platelet adhesion and activation mediated 
through sub-endothelial collagen layer [23]. The initiating event in the atherogenic 
process is some form of overt injury to the intimal endothelial lining that is induced 
by noxious substances (e.g., oxidized cholesterol, cigarette smoke, hyperlipidemia, 
hypercholesterolemia, hyperglycemia, etc.) or altered hemodynamic sheer stress 
(e.g., abnormal blood flow caused by hypertension) [24].In particular, local endo-
thelial mechanical tearing was seen as the inciting stimulus for platelet adhesion, 
activation, and the localized release of platelet-derived growth factors. This would 
then elicit the migration, proliferation, and phenotypic modulation of medial 
smooth muscle cells and thus generate a fibromuscular plaque [25]. It is of great 
interest to establish the sequential event that leads to atherogenesis from endothelial 
injury. But, the direct link between endothelial injury and the genesis of athero-
sclerotic lesion is still unclear. However, the detailed morphologic examination in 
diet-induced fatty streak lesions in animal models failed to demonstrate uncon-
cealed intimal injury or platelet adhesion. In this context, it is highly relevant that 
several molecules including high mobility group protein (HMGB-1) [26] and heat 
shock proteins (HSPs) [27] are released from injured endothelial cells and facilitate 
monocyte adhesion, a crucial step for plaque formation.
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4. Endothelial dysfunction in atherosclerosis
Endothelial dysfunction of lesion-prone areas of the arterial vasculature leads to 
atherosclerotic plaque formation [28]. Sequential deterioration of arterial vascula-
ture along with increased sheer stress contributes to lesion formation. Endothelial 
dysfunction is one of the early events that are responsible for the deterioration of 
arterial vasculature [29]. Recent insight into the cellular mechanisms involved in 
atherogenesis shows that deleterious modifications of endothelial physiology or 
metabolism is the initial event of vascular remodeling that represents a crucial step 
in the development of atherosclerosis and are also involved in the development 
of plaque and the occurrence of atherosclerosis [2]. The sequential event includ-
ing focal permeation, trapping, and physicochemical modification of circulating 
lipoprotein particles in the sub-endothelial space constructs an inflammatory 
lesion [30]. This initiates a coordinated cellular signaling, followed by complex 
pathogenic sequence and endothelial activation. Activated endothelial cells express 
several cell adhesion molecules, which facilitate selective recruitment of circulating 
monocytes from the blood, and invade the tunica intima, where they differenti-
ate into macrophages. These macrophages also abnormally take up modified 
lipoproteins to become foam cells (the hallmark of early fatty streak lesions) [31, 
32]. The activated endothelium and macrophages release multiple chemokine and 
growth factors which act on neighboring smooth muscle cells (or precursors cell) 
[33] to induce their proliferation and synthesis of extracellular matrix components 
within the intimal compartment, thus generating a fibromuscular plaque34. This 
progressive structural remodeling of developing lesions results in the formation of 
a fibrous cap, overlying a lipid-rich necrotic core that consists of oxidized lipopro-
teins, cholesterol crystals, and cellular debris. This is also accompanied by varying 
degrees of matrix remodeling and calcification [34, 35]. The lateral edges of these 
complicated plaques also contain a rich population of inflammatory cells, that 
is, activated macrophages, T-lymphocyte, and dendritic cells [36], which secrete 
several cytokines and chemokines that further activate endothelial pro-inflam-
matory phenotype and contribute to structural instability of the plaque through 
release of proteolytic enzymes (matrix metalloproteases) that lead to modifica-
tion of sub-endothelial matrix components [37]. Another aspect of atherogenesis 
is governed by lipoproteins, mainly low-density lipoproteins (LDL). This initial 
arterial remodeling through accumulation of lipids is known as fatty streak forma-
tion. The first changes in the arterial wall occur at the branch points of arteries, 
where adaptive intimal thickening occurs in response to normal hemodynamic 
stresses [38]. During the early stage of atherogenesis, LDL particles leave the blood 
and enter the arterial intima, composed of endothelial cells. Fat droplets (LDL) 
may also accumulate in the cytoplasm of vascular smooth muscle cells (VSMCs) 
[35]. LDL particles are then modified by enzymes and are oxidized into a highly 
reactive pro-inflammatory molecule (oxidized LDL), that is recognized by pattern 
recognition receptors, that is, Toll-like receptors (TLRs) present in endothelial cells 
as well as pro-inflammatory macrophages [39]. Oxidized LDL incites the reaction 
of the innate inflammatory system within the intima and contributes to vascular 
remodeling. Inflammation begins when activated endothelial cells (through TLRs) 
express cell adhesion molecules and VSMCs secrete chemokines and chemoattrac-
tants, which together draw monocytes, lymphocytes, mast cells, and neutrophils 
into the arterial wall [40]. Once monocytes enter into the arterial wall through 
the intima, they become activated into macrophages. These macrophages take up 
lipids as multiple small inclusions and become transferred into foam cells [41]. The 
degree of lipid accumulation is critical for early stage diagnosis of atherosclerosis. 
Atherosclerosis is believed to start when the lipid accumulation appears as confluent 
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extracellular lipid pools and extracellular lipid cores with and decreased cellular-
ity [42]. Endothelial cell dysfunction is also responsible for VSMC proliferation 
and differentiation to myofibroblast. In an intact vessel, VSMCs never come into 
contact with plasma proteins and are therefore devoid of growth factor present in 
plasma. In physiological conditions, VSMCs are always maintained in quiescent 
states. During early inflammation and endothelial cell activation, VSMCs receive 
signal from dying cells or growth factors that modify VSMCs to myofibroblast 
(more proliferative counterpart). Altered VSMCs (myofibroblast) also secrete 
proteoglycans, collagen, and elastic fibers into the sub-endothelial matrix [43]. This 
transformation of VSMCs further worsens the histological structure and leads to 
formation of thin-cap fibroatheroma formation [44]. Fibroatheroma can be of two 
different types depending on the content and stability of the plaque. Stability of the 
plaque also determines the fate of the fibroatheroma. Unstable fibroatheroma leads 
to thrombotic plaque formation, whereas stable fibroatheroma accumulates cal-
cium, becomes stiff, and eventually leads to occlusion [44, 45]. Unstable or vulner-
able plaques may lead to a catastrophic transition into atherosclerotic lesion—frank 
plaque rupture, with luminal release of the highly thrombogenic contents [46, 
47]. Else, some significant clinical sequelae can be seen from superficial intimal 
erosions, without any indication of plaque rupture [48]. Therefore, lately an acute 
transition appears leading to endothelial cell apoptosis, with localized endothelial 
denudation and thrombus formation leading to obstruction in regional blood flow 
[49, 50], whereas the stable lesions, having thick fibrous cap and less lipid as well as 
inflammatory cell content, can gradually invade on the lumen of the vessel caus-
ing ischemic symptoms without atherothrombotic events [51, 52]. Many ruptures 
of thin fibrous caps are clinically silent in that they heal by forming fibrous tissue 
matrices of cells, collagen fibers, and extracellular space but may rupture again with 
thrombus formation of the necrotic core, triggering an atherothrombotic occlusion. 
These cyclic changes of rupture, thrombosis, and healing may recur as many as 
four times at a single site in the arterial wall, resulting in multiple layers of healed 
tissue. In all these steps, calcium deposition in the wall of the vessels forms small 
aggregates initially, which turns into large nodules at later stage. In later stage, these 
plaques may rupture and expose the nodules, and it became sites for thrombus 
formation [47]. Therefore, the increasing number of plaques itself might become 
adequate to form significant stenosis, which may cause a shattering ischemic event 
due to flow restriction [53]. Based on its multiple regulatory roles throughout this 
complex series of events, it is evident that endothelial dysfunction constitutes a 
well-coordinated multicellular pathogenic sequence that leads to atherosclerosis.
5. Endothelial dysfunction in hypertension
Hypertension affects significantly to worldwide cardiovascular morbidity 
and mortality and is considered as a diagnostic factor for cardiovascular disease. 
Hypertension appears to have a complex association with endothelial dysfunction, a 
phenotypical alteration of the vascular endothelium that precedes the development 
of adverse cardiovascular events. Endothelial cells along with the vascular smooth 
muscle cells of resistance vessels (arteries and arterioles) regulate hypertension 
[54] as they continuously constrict and dilate according to the rhythm of cardiac 
cycle. In response to the blood flow (perfusion), the quiescent healthy endothelium 
continuously releases potent vasodilators, which have the potential to lower vas-
cular resistance, thereby regulating the blood pressure [55]. In normal condition, 
basal perfusion is determined by cardiac output, systemic, and local resistance. In 
an intact healthy vessel, endothelial cell always maintains a vasodilatory rather than 
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a vasoconstrictive phenotype. Endothelial dysfunction is a condition comprising 
not only attenuated endothelium-dependent vasodilatation but also an augmented 
inflammatory endothelial activation that leads to vasoconstriction. Endothelial 
dysfunction contributes to hypertension, whereas hypertension also leads to endo-
thelial dysfunction. In healthy endothelial tissues, a balance between endothelium-
derived relaxing factors (EDRFs) and endothelium-derived contracting factors 
(EDCFs) is maintained. Endothelial dysfunction disturbs this balance. Several 
vasodilatory and vasoconstrictive factors regulate this balance. The endothelium 
secretes a number of vasodilator factors including NO. Generation of NO can 
activate guanylate cyclase (cGMP), which causes vasodilation through relaxation of 
vascular smooth muscle cells [56]. Another vasodilatory factor PGI2 secreted by the 
endothelium inhibits platelet aggregation and vascular smooth muscle cell prolifer-
ation [57]. Endothelial cells also secrete several vascular contracting factors includ-
ing angiotensin-II (Ang-II), endothelin-I (ET-I), dinucleotide uridine adenosine 
tetraphosphate (UP4A), and COX-derived TXA2 [58]. Endothelins (ETs) are potent 
vasoconstrictor molecules having a key role in vascular homeostasis. Although there 
are three types of ET, vascular ECs mainly produce only ET-1, which has prominent 
roles in vasoconstriction. Active ET molecule is generated by the actions of an ET 
converting enzyme (ECE) found on the endothelial cell membranes. There are two 
basic types of ET-1 receptors: ET-A and ET-B, G-protein coupled receptors. Under 
normal conditions, the ET-A receptor is dominant in blood vessels [59]. ET-1 exerts 
vasoconstriction through activation of dihydropyridine channel or DHP channel 
or long lasting Ca++ channels (L-type) by binding to ET-A receptors on vascular 
smooth muscle cells. Smooth muscle cells expressed both ET-A and ET-B receptors. 
However, endothelial cells express only ET-B receptors, which negatively regulate 
NO release. Another vasorelaxation factor adenosine released from endothelial 
cells acts through purinergic receptor and maintains vascular perfusion [60]. Other 
than these factors, several cytokines and chemokines also play an important role in 
hypertension. Inflammatory cytokine induces generation of reactive oxygen species 
(ROS), one of the critical factors that link endothelial dysfunction and hyperten-
sion [61]. It is well established that Ang-II induces NADPH oxidases (NOX). But 
recent finding indicates additional source of ROS generation. In small subcutaneous 
arteries, a significant portion of Ang-II induced ROS is produced by COX-2. In the 
mouse aorta, the mitochondrial monoamine oxidase is another mediator of ROS 
generation and Ang-II or inflammation-induced endothelial dysfunction [62]. 
Therefore, mitochondrial monoamine oxidase-A and monoamine oxidase-B are 
also induced due to endothelial dysfunction in the vessels and generate a significant 
amount of H2O2 sufficient to quench endothelial NO. In spite of that, other mito-
chondrial ROS generating systems, that is, p66Shc, also contribute to hypertension-
induced ROS production. ROS production is also regulated by several intracellular 
signaling, which further attenuate endothelial dysfunction and hypertension.
6. Endothelial dysfunction in heart failure
Heart failure (HF) is the most common cause of hospitalization in cardiovascu-
lar disease with a high mortality rate. Despite novel treatment options for patients 
suffering from HF, morbidity and mortality rates are still high. The impact of the 
growing HF on global public health is a great concern in health care research. With 
the advancement of medical management, survival of acute coronary disease and 
cardiac ischemia has been improved. However, in myocardial infarction, prognosis 
is still poor, as HF with preserved ejection fraction (HFpEF) has a 65% mortal-
ity rate at 5 years. While the heart as the failing “pumping” organ was an initial 
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focus in research and treatment, neurohumoral activation and subsequently the 
role of a failing endothelium were recognized and investigated in recent years. 
Traditionally, HF was recognized as impairment of cardiac muscle activity, known 
as cardiomyopathy. Later, it was found that altered perfusion in cardiac arteries due 
to atherogenesis also contributes to cardiac ischemia that leads to cardiomyopathy. 
Reduced myocardial perfusion due to impaired ventricular function is at least in 
part a consequence of reduced endothelium-dependent vasodilator capacity of 
coronary arteries. The prominent regulatory activity of the vascular endothelium 
in HF was discovered about two decades ago, and its assessment in different cardio-
vascular disorders, including HF, has been the focus of intense research [63]. On the 
other hand, declined peripheral vasodilation causes higher systemic and pulmonary 
vascular resistance and together with stiffness of conductance arteries leads to 
increased afterload. Elevated afterload further increases cardiac workload and 
therefore worsens myocardial function. The decreased exercise capability is aggra-
vated by vasomotor dysfunction of the skeletal muscle vessel by increases vascular 
resistance. Altered endothelial metabolism further contributes to increasing cardiac 
afterload [13]. Indeed, various aspects of endothelial function are affected in heart 
failure, including vasomotor, hemostatic, antioxidant, and anti-inflammatory 
activities [63, 64]. Differences also exist in the pattern of endothelial dysfunc-
tion depending on etiology, severity, and stability of HF in individual patients. 
Endothelial dysfunction also plays a central role in HF. The failing heart is charac-
terized by an altered redox state with overproduction of ROS. The increasing evi-
dence suggests that the abnormal cardiac and vascular phenotypes characterizing 
the failing heart are caused in large part by imbalances between NO bioavailability 
and oxidative stress [65]. During initial stages of HF, inflammatory mediators from 
the myocardium and altered local shear forces modulate gene expression, leuko-
cyte infiltration, increased cytokine production, increased ROS generation, and 
diminished NO bioavailability. Clinical studies showed significant up-regulation of 
plasma markers of endothelial activation (e.g. E-selectin) and endothelial dam-
age (e.g. vWF) in HF [22, 63]. However, it is difficult to determine if endothelial 
dysfunction is the cause or effect of the HF. Therefore, HF is regarded as thrombotic 
complication. As mentioned earlier, during atherogenesis, decreased lumen of 
cardiac arteries leads to reduced perfusion to the heart muscle. This phenomenon is 
coupled with increased sheer stress and impaired blood flow. This reduced perfu-
sion either led to ischemia–reperfusion injury or coronary artery thrombosis [63]. 
Studies showed that endothelial dysfunction is one of the principle mediators of 
ischemia–reperfusion injury and thrombosis. This explains the increased endothe-
lial dysfunction markers in coronary artery disease, HF, and thrombosis.
7. Endothelial dysfunction in stroke
The global burden of neurological diseases including cerebrovascular stroke 
has significantly increased, and development of new treatment modalities for 
cerebrovascular diseases is an urgent need. Cerebrovascular stroke can be broadly 
subdivided into acute ischemic stroke and hemorrhagic stroke [66]. Acute 
ischemic stroke is among the leading causes of death and long-term disability. 
Cerebrovascular stroke in small vessel has functional (lacunar stroke, cognitive 
impairment, gait, and movement disorders) and structural (small subcortical 
infarct, lacunar infarct, lacunes, white matter lesions, and micro bleeds) conse-
quences. In the past few decades, the immense development of neuro-radiological 
methods enabled better imaging of cerebral blood vessels. From the clinical point 
of view, it is very important to identify the location of vascular lesion. However, 
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the treatment strategies do not depend on the location of vascular impairment. 
It is now well recognized that endothelial dysfunction represents a systemic 
syndrome involving multiple vascular beds, including the cerebral vasculature 
[67]. Endothelial function is not uniform throughout the arterial system. It dif-
fers between organs and potentially also between different vascular beds within 
the same organ. Cerebral endothelium is probably one of the most specific types 
since it is the crucial element of the well-known blood-brain barrier (BBB). The 
BBB is a term used to describe the unique properties of the microvasculature of 
the central nervous system that protects the brain from harmful agents and patho-
gens [68]. CNS vessels are continuous non-fenestrated vessels, but also contain a 
series of additional properties that allow them to tightly regulate the movement of 
molecules, ions, and cells between the blood and the CNS. This heavily restricting 
barrier capacity allows BBB ECs to tightly regulate CNS homeostasis, which is criti-
cal to allow for proper neuronal function, as well as protect the CNS from toxins, 
pathogens, inflammation, injury, and disease. The cell-to-cell interaction with 
astrocytes, microglia, and neurons mainly played an important role for mainte-
nance of BBB controlled by endothelial cells and pericytes [69].
However, the integrity of BBB is mainly disrupted due to decrease in endothelial 
cell-cell junction proteins and the detachment of pericytes from the endothelial 
membrane in homorganic condition [70]. Cerebral autoregulation maintains 
constant blood flow (CBF) through the brain in spite of changing mean arterial 
pressure. Autoregulation of cerebral blood flow consists of mechano- and chemo-
regulation. The serum level of carbon dioxide (CO2) is directly controlled by the 
chemo-regulation independent of changes in mean arterial pressure [71]. However, 
mechano-regulation depends on transmural pressure gradient and endothelial 
vasodilatation.
8. Conclusion
From the above discussion, it is evident that CVDs and cardiovascular morbid-
ity are associated with endothelial dysfunction, but the mechanistic links between 
inflammatory diseases, endothelial dysfunction, and CVDs have not been fully elu-
cidated. The role of traditional cardiovascular risk factors in patients with inflam-
mation, especially sterile inflammation, has received considerable attention, though 
traditional factors alone are insufficient to explain the excess burden of CVDs. It 
seems likely that sterile inflammation, a shared feature of CVDs, is involved in the 
pathogenesis of accelerated endothelial dysfunction.
Patients with chronic inflammatory/and or sterile inflammatory diseases are 
at high risk for cardiovascular morbidity and mortality. In many inflammatory 
diseases, this heightened risk of CVDs is reflected in early endothelial dysfunction, 
even in the absence of any other detectable diseases. Several others mechanisms, 
that is, auto-antibodies, oxidative stress, and interactions with traditional risk fac-
tors like dyslipidemia and insulin resistance might be involved. Therefore, further 
research in future is required to delineate the importance of these processes. So, the 
current approaches to diminish cardiovascular morbidity and mortality are focused 
on controlling traditional modifiable cardiovascular risk factors and reduction of 
disease risk. Therefore, the precise mechanisms leading to development of CVDs 
due to inflammation/or sterile inflammation need to explore. These studies might 
help to identify unique therapeutic targets to combat these diseases.
The endothelium therefore represents an integrator of vascular risk, and the 
study of its dysfunction may help elucidate mechanisms driving accelerated CVDs 
in future, which could help to develop therapeutic targets for control of CVDs.
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